Nanjing Leads Biolabs says Phase II Opamtistomig trial in first-line liver cancer enters expansion phase

• Nanjing Leads Biolabs reported its Phase II study of LBL-024 (opamtistomig) for first-line hepatocellular carcinoma entered the expansion phase.
• Results have already been reviewed from the safety run-in phase; no future presentation timing was disclosed.
• Preliminary findings showed encouraging anti-tumor activity for LBL-024 with bevacizumab, alongside a favorable safety and tolerability profile.
• The update supports a broader development strategy for LBL-024 as a PD-L1/4-1BB bispecific positioned for multiple solid-tumor indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260806-12274262), on August 05, 2026, and is solely responsible for the information contained therein.